-+ 0.00%
-+ 0.00%
-+ 0.00%

Chardan Capital Maintains Buy on Stoke Therapeutics, Maintains $24 Price Target

Benzinga·03/19/2025 11:38:31
Listen to the news
Chardan Capital analyst Rudy Li maintains Stoke Therapeutics (NASDAQ:STOK) with a Buy and maintains $24 price target.